Search

Your search keyword '"Cadinha S"' showing total 28 results
Start Over Author "Cadinha S"
28 results on '"Cadinha S"'

7. 7th Drug hypersensitivity meeting: part two

Author

Elera, J.D., Boteanu, C., Blanco, M.A.J., Gonzalez-Mendiola, R., García, I.C., Alvarez, A., Martinez, J.J.L., Garrido, J.M., Barona, C.T., Chorda, C.P., Salgueiro, R.L., Palacios, M.D., De Rojas, D.H.F., Acar, E.A., Aktas, A., Ermertcan, A.T., Temiz, C., Lin, C-Y, Hui, C-Y.R., Chang, Y-C, Yang, C-H, Chung, W-H, Carolino, F., Silva, D., De Castro, E.D., Cernadas, J.R., Ensina, L.F., Aranda, C., Nunes, I.C., Lacerda, A., Martins, A.M., Goudouris, E., Ribeiro, M., Da Silva Franco, J.F., Queiroz, L., Solé, D., Dalgiç, C.T., Sin, A.Z., Günsen, F.D., Bulut, G., Ardeniz, F.Ö., Gülbahar, O., Gökmen, E.N.M., Kokuludag, A., De Francisco, A.M.M., De Vicente Jiménez, T.M., Mendoza Parra, A.M., Burgos Pimentel, A.M., Luque, A.G., Amaral, L., Leão, L.C., Pinto, N., Belo, J., Marques, J., Carreiro-Martins, P., Leiria-Pinto, P., Chaabane, A., Romdhane, H.B., Fredj, N.B., Chadly, Z., Boughattas, N.A., Aouam, K., Uyttebroek, A.P., Bridts, C.H., Romano, A., Ebo, D.G., Sabato, V., Lopes, A., Cosme, J., Aguiar, R., Lourenço, T., Paes, M-J, Spínola-Santos, A., Pereira-Barbosa, M., Cruz, C.R., Dos Reis, R.P., Tomaz, E., Pires, A.P., Inácio, F., Benito-Garcia, F., Mota, I., Correia, M., Gaspar, Â., Chambel, M., Piedade, S., Morais-Almeida, M., Nakonechna, A., Antipkin, Y., Umanets, T., Pineda, F., Arribas, F., Lapshyn, V., Miranda, P.A., De La Cruz Hoyos, B., Blanco, A.J., Del Pozo, M., Vultaggio, A., Nencini, F., Pratesi, S., Matucci, A., Maggi, E., Cegec, I., Nahal, D.J., Turk, V.E., Aumiler, M.R., Ausperger, K.M., Kraljickovic, I., Simic, I., Yamaguchi, Y., Watanabe, T., Satoh, M., Tanegashima, T., Oda, K., Wada, H., Aihara, M., Lee, J.J., Choi, J.C., Lee, H.Y., Fernandes, R-A.R., Faria, E., Pita, J., Sousa, N., Ribeiro, C., Carrapatoso, I., Bom, A.T., Rodolfo, A., Dias-Castro, E., Voronova, M., Valle, D.K., Coronel, V.P., Chordá, C.P., Madamba, R.C.Y., Ferrer, M., Goikoetxea, M.J., D’Amelio, C., Bernad, A., Vega, O., Gastaminza, G., Bibián, B.L., Salazar, M.L., Vilà-Nadal, G., Roman, A.M.F., Ortega, J.D., Muñoz, M.G., Gancedo, S.Q., Moreno, M.R.C., Hofmeier, K.S., Barzylovych, V., Pola, B., Lluncor, M., Fiandor, A., Bellón, T., Domínguez, J., Quirce, S., Yang, M-S, Kim, S-S, Kim, S-H, Kang, H-R, Park, H-W, Cho, S-H, Min, K-U, Chang, Y-S, Delahaye, C., Flabbee, J., Waton, J., Bauvin, O., Barbaud, A., Fadhel, N.B., Gulin, S.J., Chiriac, A., Cardoso, B.K., Viseu, R., Moreira, A., Cadinha, S., Neves, A.C., Barreira, P., Malheiro, D., Da Silva, J.P., Jurakic-Toncic, R., Ljubojevic, S., Turcic, P., Gilissen, L., Huygens, S., Goossens, A., Andreu, I., Romero, A.M., Cabezas, P.G., Parejo, P.A., Del Carmen Plaza-Serón, M., Doña, I., Blanca-López, N., Flores, C., Galindo, M.L., Molina, A., Perkins, J.R., Cornejo-García, J.A., García-Agúndez, J.A., García-Martín, E., Campo, P., Canto, M.G., Blanca, M., Guéant-Rodríguez, R.M., Jurado-Escobar, R., Barrionuevo, E., Salas, M., Canto, G., Guéant, J-L, Usui, T., Tailor, A., Faulkner, L., Farrell, J., Alfirevic, A., Kevin Park, B., Naisbitt, D.J., Trelles, O., Guerrero, M.A., Upton, A., Ueta, M., Sawai, H., Sotozono, C., Tokunaga, K., Kinoshita, S., Sukasem, C., Satapornpong, P., Tempark, T., Rerknimitr, P., Pairayayutakul, K., Klaewsongkram, J., Koomdee, N., Jantararoungtong, T., Santon, S., Puangpetch, A., Intusoma, U., Tassaneeyakul, W., Theeramoke, V., Ramirez, E., Borobia, A.M., Tong, H., Castañer, J.L., De Abajo, F.J., Galvao, V.R., Pavlos, R., McKinnon, E., Williams, K., Beeghly-Fadiel, A., Phillips, E., Castells, M., Boni, E., Russello, M., Mauro, M., Ue, K.L., Rutkowski, K., Gomis, V.S., Ferre, J.F., Rodriguez, A.E., Reig, V.C., Sanchez, J.F., Breynaert, C., Van Hoeyveld, E., Schrijvers, R., Irigoyen, R.F., Collado, D., Vida, Y., Najera, F., Perez-Inestrosa, E., Mesa-Antunez, P., Mayorga, C., Torres, M.J., Tannert, L.K., Mortz, C.G., Skov, P.S., Bindslev-Jensen, C., Pfützner, W., Dörnbach, H., Visse, J., Rauber, M., Möbs, C., Elzagallaai, A.A., Chow, L., Abuzgaia, A.M., Rieder, M.J., Trubiano, J., Woolnough, E., Cheng, C., Kato, K., Azukizawa, H., Hanafusa, T., Katayama, I., Fujiyama, T., Hashizume, H., Umayahara, T., Ito, T., Tokura, Y., Silar, M., Zidarn, M., Rupnik, H., Korosec, P., Redwood, A.J., Strautins, K., White, K., Chopra, A., Konvinse, K., Leary, S., Mallal, S., Cabañas, R., Fiandor, A.M., Sullivan, A., Whitaker, P., Peckham, D., Haw, W.Y., Polak, M.E., Mcguire, C., Ardern-Jones, M.R., Aoyama, Y., Shiohara, T., Correia, S., Gelincik, A., Demir, S., Sen, F., Bozbey, H.U., Olgac, M., Unal, D., Coskun, R., Colakoglu, B., Buyuozturk, S., Çatin-Aktas, E., Deniz, G., Laguna, J.J., Dionicio, J., Fernandez, T., Olazabal, I., Ruiz, M.D., Lafuente, A., Núñez, J., Fernández, T.D., Palomares, F., Fernández, R., Sanchez, M.I., Ruiz, A., Ariza, A., Alonso, A.B., Garófalo, C.D., Matute, O.V., Puga, M.F., Lapresa, M.J.G., Lasarte, G.G., Thinnes, A., Merk, H.F., Baron, J.M., Leverkus, M., Balakirski, G., Gibson, A., Ogese, M., Al-Attar, Z., Yaseen, F., Meng, X., Jenkins, R., Farrel, J., Alhilali, K., Xue, Y., Illing, P., Mifsud, N., Fettke, H., Lai, J., Ho, R., Kwan, P., Purcell, A., Ogese, M.O., Betts, C., Thomson, P., Alhaidari, M., Berry, N., O’Neill, P.M., Alzahrani, A., Azoury, M.E., Fili, L., Bechara, R., Scornet, N., Nhim, C., Weaver, R., Claude, N., Joseph, D., Maillere, B., Parronchi, P., Pallardy, M., Villani, A.P., Rozières, A., Bensaïd, B., Tardieu, M., Albert, F., Mutez, V., Baysal, T., Maryanski, J., Nicolas, J-F, Kanagawa, O., Vocanson, M., Hung, S-L, Harrison, C.J., Jenkins, R.E., French, N.S., Montañez, M.I., Fernandez, T.D., Martin-Serrano, A., Molina, N., Wood, S., Pirmohamed, M., Martín-Serrano, Á., Pérez-Inestrosa, E., Pérez-Sala, D., Guzmán, A.E., Ko, T-M, Chen, Y-T, Wu, J-Y, Sánchez-Gómez, F.J., González-Morena, J.M., Arreola, A.M., Corona, J.A.B., Flores, S.M., Cherit, J.D., Figueroa, N.V.D., Flores, J.L.C., Perkins, J., Pérez-Alzate, D., Bogas, G., Marti, L.M.T., De La Losa, F.P., Poves, F.A., Lopez, J.T., Santiago, T.L., Elera, J.D., Boteanu, C., Blanco, M.A.J., Gonzalez-Mendiola, R., García, I.C., Alvarez, A., Martinez, J.J.L., Garrido, J.M., Barona, C.T., Chorda, C.P., Salgueiro, R.L., Palacios, M.D., De Rojas, D.H.F., Acar, E.A., Aktas, A., Ermertcan, A.T., Temiz, C., Lin, C-Y, Hui, C-Y.R., Chang, Y-C, Yang, C-H, Chung, W-H, Carolino, F., Silva, D., De Castro, E.D., Cernadas, J.R., Ensina, L.F., Aranda, C., Nunes, I.C., Lacerda, A., Martins, A.M., Goudouris, E., Ribeiro, M., Da Silva Franco, J.F., Queiroz, L., Solé, D., Dalgiç, C.T., Sin, A.Z., Günsen, F.D., Bulut, G., Ardeniz, F.Ö., Gülbahar, O., Gökmen, E.N.M., Kokuludag, A., De Francisco, A.M.M., De Vicente Jiménez, T.M., Mendoza Parra, A.M., Burgos Pimentel, A.M., Luque, A.G., Amaral, L., Leão, L.C., Pinto, N., Belo, J., Marques, J., Carreiro-Martins, P., Leiria-Pinto, P., Chaabane, A., Romdhane, H.B., Fredj, N.B., Chadly, Z., Boughattas, N.A., Aouam, K., Uyttebroek, A.P., Bridts, C.H., Romano, A., Ebo, D.G., Sabato, V., Lopes, A., Cosme, J., Aguiar, R., Lourenço, T., Paes, M-J, Spínola-Santos, A., Pereira-Barbosa, M., Cruz, C.R., Dos Reis, R.P., Tomaz, E., Pires, A.P., Inácio, F., Benito-Garcia, F., Mota, I., Correia, M., Gaspar, Â., Chambel, M., Piedade, S., Morais-Almeida, M., Nakonechna, A., Antipkin, Y., Umanets, T., Pineda, F., Arribas, F., Lapshyn, V., Miranda, P.A., De La Cruz Hoyos, B., Blanco, A.J., Del Pozo, M., Vultaggio, A., Nencini, F., Pratesi, S., Matucci, A., Maggi, E., Cegec, I., Nahal, D.J., Turk, V.E., Aumiler, M.R., Ausperger, K.M., Kraljickovic, I., Simic, I., Yamaguchi, Y., Watanabe, T., Satoh, M., Tanegashima, T., Oda, K., Wada, H., Aihara, M., Lee, J.J., Choi, J.C., Lee, H.Y., Fernandes, R-A.R., Faria, E., Pita, J., Sousa, N., Ribeiro, C., Carrapatoso, I., Bom, A.T., Rodolfo, A., Dias-Castro, E., Voronova, M., Valle, D.K., Coronel, V.P., Chordá, C.P., Madamba, R.C.Y., Ferrer, M., Goikoetxea, M.J., D’Amelio, C., Bernad, A., Vega, O., Gastaminza, G., Bibián, B.L., Salazar, M.L., Vilà-Nadal, G., Roman, A.M.F., Ortega, J.D., Muñoz, M.G., Gancedo, S.Q., Moreno, M.R.C., Hofmeier, K.S., Barzylovych, V., Pola, B., Lluncor, M., Fiandor, A., Bellón, T., Domínguez, J., Quirce, S., Yang, M-S, Kim, S-S, Kim, S-H, Kang, H-R, Park, H-W, Cho, S-H, Min, K-U, Chang, Y-S, Delahaye, C., Flabbee, J., Waton, J., Bauvin, O., Barbaud, A., Fadhel, N.B., Gulin, S.J., Chiriac, A., Cardoso, B.K., Viseu, R., Moreira, A., Cadinha, S., Neves, A.C., Barreira, P., Malheiro, D., Da Silva, J.P., Jurakic-Toncic, R., Ljubojevic, S., Turcic, P., Gilissen, L., Huygens, S., Goossens, A., Andreu, I., Romero, A.M., Cabezas, P.G., Parejo, P.A., Del Carmen Plaza-Serón, M., Doña, I., Blanca-López, N., Flores, C., Galindo, M.L., Molina, A., Perkins, J.R., Cornejo-García, J.A., García-Agúndez, J.A., García-Martín, E., Campo, P., Canto, M.G., Blanca, M., Guéant-Rodríguez, R.M., Jurado-Escobar, R., Barrionuevo, E., Salas, M., Canto, G., Guéant, J-L, Usui, T., Tailor, A., Faulkner, L., Farrell, J., Alfirevic, A., Kevin Park, B., Naisbitt, D.J., Trelles, O., Guerrero, M.A., Upton, A., Ueta, M., Sawai, H., Sotozono, C., Tokunaga, K., Kinoshita, S., Sukasem, C., Satapornpong, P., Tempark, T., Rerknimitr, P., Pairayayutakul, K., Klaewsongkram, J., Koomdee, N., Jantararoungtong, T., Santon, S., Puangpetch, A., Intusoma, U., Tassaneeyakul, W., Theeramoke, V., Ramirez, E., Borobia, A.M., Tong, H., Castañer, J.L., De Abajo, F.J., Galvao, V.R., Pavlos, R., McKinnon, E., Williams, K., Beeghly-Fadiel, A., Phillips, E., Castells, M., Boni, E., Russello, M., Mauro, M., Ue, K.L., Rutkowski, K., Gomis, V.S., Ferre, J.F., Rodriguez, A.E., Reig, V.C., Sanchez, J.F., Breynaert, C., Van Hoeyveld, E., Schrijvers, R., Irigoyen, R.F., Collado, D., Vida, Y., Najera, F., Perez-Inestrosa, E., Mesa-Antunez, P., Mayorga, C., Torres, M.J., Tannert, L.K., Mortz, C.G., Skov, P.S., Bindslev-Jensen, C., Pfützner, W., Dörnbach, H., Visse, J., Rauber, M., Möbs, C., Elzagallaai, A.A., Chow, L., Abuzgaia, A.M., Rieder, M.J., Trubiano, J., Woolnough, E., Cheng, C., Kato, K., Azukizawa, H., Hanafusa, T., Katayama, I., Fujiyama, T., Hashizume, H., Umayahara, T., Ito, T., Tokura, Y., Silar, M., Zidarn, M., Rupnik, H., Korosec, P., Redwood, A.J., Strautins, K., White, K., Chopra, A., Konvinse, K., Leary, S., Mallal, S., Cabañas, R., Fiandor, A.M., Sullivan, A., Whitaker, P., Peckham, D., Haw, W.Y., Polak, M.E., Mcguire, C., Ardern-Jones, M.R., Aoyama, Y., Shiohara, T., Correia, S., Gelincik, A., Demir, S., Sen, F., Bozbey, H.U., Olgac, M., Unal, D., Coskun, R., Colakoglu, B., Buyuozturk, S., Çatin-Aktas, E., Deniz, G., Laguna, J.J., Dionicio, J., Fernandez, T., Olazabal, I., Ruiz, M.D., Lafuente, A., Núñez, J., Fernández, T.D., Palomares, F., Fernández, R., Sanchez, M.I., Ruiz, A., Ariza, A., Alonso, A.B., Garófalo, C.D., Matute, O.V., Puga, M.F., Lapresa, M.J.G., Lasarte, G.G., Thinnes, A., Merk, H.F., Baron, J.M., Leverkus, M., Balakirski, G., Gibson, A., Ogese, M., Al-Attar, Z., Yaseen, F., Meng, X., Jenkins, R., Farrel, J., Alhilali, K., Xue, Y., Illing, P., Mifsud, N., Fettke, H., Lai, J., Ho, R., Kwan, P., Purcell, A., Ogese, M.O., Betts, C., Thomson, P., Alhaidari, M., Berry, N., O’Neill, P.M., Alzahrani, A., Azoury, M.E., Fili, L., Bechara, R., Scornet, N., Nhim, C., Weaver, R., Claude, N., Joseph, D., Maillere, B., Parronchi, P., Pallardy, M., Villani, A.P., Rozières, A., Bensaïd, B., Tardieu, M., Albert, F., Mutez, V., Baysal, T., Maryanski, J., Nicolas, J-F, Kanagawa, O., Vocanson, M., Hung, S-L, Harrison, C.J., Jenkins, R.E., French, N.S., Montañez, M.I., Fernandez, T.D., Martin-Serrano, A., Molina, N., Wood, S., Pirmohamed, M., Martín-Serrano, Á., Pérez-Inestrosa, E., Pérez-Sala, D., Guzmán, A.E., Ko, T-M, Chen, Y-T, Wu, J-Y, Sánchez-Gómez, F.J., González-Morena, J.M., Arreola, A.M., Corona, J.A.B., Flores, S.M., Cherit, J.D., Figueroa, N.V.D., Flores, J.L.C., Perkins, J., Pérez-Alzate, D., Bogas, G., Marti, L.M.T., De La Losa, F.P., Poves, F.A., Lopez, J.T., and Santiago, T.L.

Abstract

No abstract available

Published
2016

8. Pneumonite Crónica da Infância

Author

Castro Correia, C., Souto-Moura, C., Cadinha, S., Freitas, S., Sobrinho-Simoes, J., and Ines Azevedo

Subjects
lcsh:R5-920, lcsh:RJ1-570, lcsh:Pediatrics, lcsh:Medicine (General)
Abstract

Resumo As doenças pulmonares intersticiais (DPI) crónicas caracterizam-se por persistência ou recorrência de dispneia e/ou tosse, de desenvolvimento insidioso e duração superior a um mês, pela presença de infiltrados pulmonares bilaterais e por alterações das trocas gasosas. A prevalência na idade pediátrica é muito baixa e o diagnóstico etiológico e o tratamento são, em regra, difíceis. Em 1995, Katzenstein e colegas descreveram uma nova variante histológica, que ocorre exclusivamente em lactentes e crianças pequenas, e designaram-na por Pneumonite Crónica da Infância (PCI). Pela sua raridade os autores apresentam um caso clínico desta doença, manifestada aos 3 meses de idade por síndrome intersticial persistente, e discutem o possível papel da infecção por vírus de Epstein-Barr na sua génese. Palavras-Chave: Pneumonite Crónica da Infância, Doenças Pulmonares Intersticiais, vírus Epstein-Barr, Portuguese Journal of Pediatrics, vol. 36 n.º 2/3 (2005)

Published
2014

9. Drug-Induced Anaphylaxis Survey in Portuguese Allergy Departments

Author

Faria, E., Rodrigues-Cernadas, J., Gaspar, Â, Botelho, C., Castro, E., Anabela Lopes, Gomes, E., Malheiro, D., Cadinha, S., Campina-Costa, S., Neto, M., Sousa, N., Rodrigues-Alves, R., Romeira, A., Caiado, J., and Morais-Almeida, M.

Subjects
Drug Hypersensitivity, Portugal, Data Collection, HDE ALER, Anaphylaxis, Disease Notification
Abstract

Background and Objective: Drug-induced anaphylaxis is an unpredictable and potentially fatal adverse drug reaction. The aim of this study was to identify the causes of drug-induced anaphylaxis in Portugal. Methods: During a 4-year period a nationwide notification system for anaphylaxis was implemented, with voluntary reporting by allergists. Data on 313 patients with drug anaphylaxis were received and reviewed. Statistical analysis included distribution tests and multiple logistic regression analysis to investigate significance, regression coefficients, and marginal effects. Results: The mean (SD) age of the patients was 43.8 (17.4) years, and 8.3% were younger than 18 years. The female to male ratio was 2:1. The main culprits were nonsteroidal anti-inflammatory drugs (NSAIDs) (47.9% of cases), antibiotics (35.5%), and anesthetic agents (6.1%). There was a predominance of mucocutaneous symptoms (92.2%), followed by respiratory symptoms (80.4%) and cardiovascular symptoms (49.0%). Patients with NSAID-induced anaphylaxis showed a tendency towards respiratory and mucocutaneous manifestations. We found no significant associations between age, sex, or atopy and type of drug. Anaphylaxis recurrence was observed in 25.6% of cases, and the risk was higher when NSAIDs were involved. Conclusions: NSAIDs were the most common cause of anaphylaxis in this study and were also associated with a higher rate of recurrence. We stress the need for better therapeutic management and prevention of recurring episodes of drug-induced anaphylaxis.

Published
2014

11. Drug-Induced Anaphylaxis: National Survey 2007-2010

Author

Faria, E., Rodrigues-Cernadas, J., Gaspar, A., Botelho, C., Castro, E., Lopes, A., Gomes, E., Malheiro, D., Cadinha, S., Campina-Costa, S., Neto, M., Sousa, N., Rodrigues-Alves, R., Romeira, A., Caiado, J., and Morais-Almeida, M.

Subjects
Hipersensibilidade a Drogas, registo português, hipersensibilidade a fármacos, HDE ALER, Notificação, Anti-Inflamatórios, Anafilaxia
Abstract

Introdução: A anafilaxia a fármacos constitui uma situação potencialmente fatal e imprevisível, desconhecendo -se a real prevalência em diferentes grupos populacionais e os factores de risco relacionados. Objectivo: Contribuir para o melhor conhecimento epidemiológico da anafilaxia induzida por fármacos no nosso país. Métodos: Durante um período de 4 anos (Janeiro de 2007 a Dezembro de 2010) foi implementado um sistema de notificação nacional de anafilaxia, focalizado na notificação voluntária por clínicos com diferenciação em patologia imunoalérgica. Foram recebidas e analisadas notificações de anafilaxia a fármacos de 313 doentes. No estudo estatístico foram aplicados testes de distribuição e análise de regressão logística múltipla para obter significância e coeficientes de regressão e efeitos marginais. Resultados: A média de idade foi de 43,8 ±17,4 anos, sendo 8% de idade inferior a 18 anos. A relação género feminino/masculino foi de 2/1. A média de idade do primeiro episódio foi de 39 ±18,2 anos. Nove doentes apresentaram mais que uma causa de anafilaxia, correspondendo a um total de 322 notificações de grupos de fármacos envolvidos. As principais causas da anafilaxia a fármacos foram os anti -inflamatórios não esteróides (AINEs), os antibióticos e os agentes anestésicos, com respectivamente 48%, 36% e 6% dos casos. Outros fármacos implicados foram citostáticos, corticosteróides, inibidores da bomba de protões e meios de contraste iodados, entre outros. Houve predomínio de manifestações mucocutâneas (92%), seguido de respiratórias (81%) e de cardiovasculares (49%). Os doentes com anafilaxia a AINEs apresentaram aumento significativo da associação de manifestações mucocutâneas e respiratórias. Não foram observadas diferenças significativas em idade, género ou antecedentes de atopia entre os diferentes grupos de fármacos envolvidos. As reacções ocorreram em ambiente hospitalar em 45% dos casos. Em 53% nos 15 minutos após a administração do fármaco e 35% motivaram internamento. A recorrência da anafilaxia foi observada em 26% e o risco foi significativamente mais elevado nos casos de anafilaxia a AINEs. Apenas 48% dos doentes receberam tratamento com adrenalina e somente em 9% dos casos foi prescrito dispositivo para auto -administração de adrenalina. Conclusões: Neste estudo os AINEs foram os fármacos mais frequentes e os mais associados a recorrência de anafilaxia. Destaca -se o sub -tratamento com adrenalina e a necessidade de serem tomadas medidas no sentido do tratamento eficaz e da prevenção da recorrência de anafilaxia a fármacos.

Published
2012

12. Anafilaxia Induzida por Fármacos: Registo Nacional 2007-2010

Author

Faria, E., Rodrigues-Cernadas, J., Gaspar, A., Botelho, C., Castro, E., Lopes, A., Gomes, E., Malheiro, D., Cadinha, S., Campina-Costa, S., Neto, M., Sousa, N., Rodrigues-Alves, R., Romeira, A., Caiado, J., and Morais-Almeida, M.

Subjects
Hipersensibilidade a Drogas, registo português, hipersensibilidade a fármacos, HDE ALER, Notificação, Anti-Inflamatórios, notification, Anaphylaxis, drug hypersensitivity, Anafilaxia, Portuguese survey
Abstract

Introdução: A anafilaxia a fármacos constitui uma situação potencialmente fatal e imprevisível, desconhecendo-se a real prevalência em diferentes grupos populacionais e os factores de risco relacionados.Objectivo: Contribuir para o melhor conhecimento epidemiológico da anafilaxia induzida por fármacos no nosso país. Métodos: Durante um período de 4 anos (Janeiro de 2007 a Dezembro de 2010) foi implementado um sistema de notificação nacional de anafilaxia, focalizado na notificação voluntária por clínicos com diferenciação em patologia imunoalérgica. Foram recebidas e analisadas notificações de anafilaxia a fármacos de 313 doentes. No estudo estatístico foram aplicados testes de distribuição e análise de regressão logística múltipla para obter significância e coeficientes de regressão e efeitos marginais. Resultados: A média de idade foi de 43,8 ±17,4 anos, sendo 8% de idade inferior a 18 anos. A relação género feminino/masculino foi de 2/1. A média de idade do primeiro episódio foi de 39 ±18,2 anos. Nove doentes apresentaram mais que uma causa de anafilaxia, correspondendo a um total de 322 notificações de grupos de fármacos envolvidos. As principais causas da anafilaxia a fármacos foram os anti-inflamatórios não esteróides (AINEs), os antibióticos e os agentes anestésicos, com respectivamente 48%, 36% e 6% dos casos. Outros fármacos implicados foram citostáticos, corticosteróides, inibidores da bomba de protões e meios de contraste iodados, entre outros. Houve predomínio de manifestações mucocutâneas (92%), seguido de respiratórias (81%) e de cardiovasculares (49%). Os doentes com anafilaxia a AINEs apresentaram aumento significativo da associação de manifestações mucocutâneas e respiratórias. Não foram observadas diferenças significativas em idade, género ou antecedentes de atopia entre os diferentes grupos de fármacos envolvidos. As reacções ocorreram em ambiente hospitalar em 45% dos casos. Em 53% nos 15 minutos após a administração do fármaco e 35% motivaram internamento. A recorrência da anafilaxia foi observada em 26% e o risco foi significativamente mais elevado nos casos de anafilaxia a AINEs. Apenas 48% dos doentes receberam tratamento com adrenalina e somente em 9% dos casos foi prescrito dispositivo para auto-administração de adrenalina. Conclusões: Neste estudo os AINEs foram os fármacos mais frequentes e os mais associados a recorrência de anafilaxia. Destaca -se o sub-tratamento com adrenalina e a necessidade de serem tomadas medidas no sentido do tratamento eficaz e da prevenção da recorrência de anafilaxia a fármacos. Background: Anaphylaxis to drugs is an unpredictable and potentially fatal adverse drug reaction. The true prevalence in different population groups and the related risk factors are mostly unknown. Objective: To contribute to better understanding the epidemiology of drug-induced anaphylaxis in our country.Methods: During a 4 years period (January 2007 to December 2010) a national notification system for anaphylaxis was implemented, focused on voluntary reporting by physicians with allergy differentiation. In this period the data from 313 patients with drug anaphylaxis have been received and analysed. The statistical analysis included distribution tests and multiple logistic regression analysis to obtain the significance, the regression coefficients and marginal effects.Results: The mean age was 43.8 ± 17.4 years, 8% younger than 18 years old. The ratio female/male was 2/1. The mean age at first episode was 39 ± 18.2 years. Nine patients had more than one cause of drug anaphylaxis, corresponding to a total of 322 reports of different groups of drugs involved. The main culprit drugs were the non -steroidal anti-inflammatory drugs (NSAIDs), antibiotics and anesthetic agents in 48%, 36% and 6% of the cases respectively. Other drugs involved were cytostatics, corticosteroids, proton pump inhibitors and iodinated contrast media, among others. There was a predominance of mucocutaneous symptoms (92%), followed by respiratory (81%) and cardiovascular (49%) symptoms. Patients with NSAIDs anaphylaxis showed a tendency to have co-respiratory and mucocutaneous manifestations. We didn’t find a significant association between age, gender and atopy within the different groups of drugs. Reactions occurred in 53% of cases within 15 minutes after drug administration, 45% of the cases occurred in inpatients and in 35% hospitalization was needed. The recurrence of anaphylaxis was observed in 26% of cases, with an increased risk when NSAIDs were involved. Only 48% of patients were treated with epinephrine and in 9% of cases an epinephrine auto-injector was prescribed.Conclusions: In this study the most frequent culprit drugs were NSAIDs and they were associated with a higher rate of recurrence of anaphylaxis. We stress the under-treatment with epinephrine and the need to achieve a better therapeutic management and prevention of recurrence of anaphylaxis to drugs.

Published
2012

13. Basophil activation test in the study of food and drug hypersensitivity reactions

Author

Carrapatoso, I, Cadinha, S, and Sanz, ML

Subjects
Hipersensibilidade a Medicamentos, Hipersensibilidade Alimentar, Basófilos
Abstract

The increase in the prevalence of adverse reactions to foods and drugs represents a constant challenge to the development of new methods of diagnosis. A meta-analysis on published studies concerning the clinical usefulness of the Basophil activation test (BAT) in these reactions was performed. High sensibilities and specificities can be achieved if certain technical requirements are observed. BAT results have a positive and high significant correlations with other routine diagnostic methods such as skin tests, serum specific IgE and oral controlled challenge. Efficacy of diagnosis can be improved with the combined use of BAT and other techniques. In order to achieve a well-conducted evaluation on the diagnosis of hypersensitivity reactions to foods and drugs the best options should be

Published
2005

22. A rare case of sevoflurane hypersensitivity.

Author

Dahlem C, Cadinha S, Delgado I, and Preto ML

Subjects
Anesthetics, Inhalation administration & dosage, Child, Drug Eruptions diagnosis, Humans, Hypersensitivity, Immediate diagnosis, Immunologic Tests, Male, Methyl Ethers administration & dosage, Predictive Value of Tests, Risk Factors, Sevoflurane, Anesthetics, Inhalation adverse effects, Drug Eruptions etiology, Hypersensitivity, Immediate chemically induced, Methyl Ethers adverse effects
Published
2016
Full Text
View/download PDF

23. Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs among Adults: Clinical Features and Risk Factors for Diagnosis Confirmation.

Author

Rebelo Gomes E, Geraldes L, Gaspar Â, Malheiro D, Cadinha S, Abreu C, Chambel M, Almeida E, and Faria E

Subjects
Adolescent, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal classification, Cross Reactions immunology, Female, Humans, Male, Middle Aged, Phenotype, Risk Factors, Skin Tests, Time Factors, Young Adult, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Drug Hypersensitivity diagnosis, Drug Hypersensitivity immunology
Abstract

Background: Nonsteroidal anti-inflammatory drugs (NSAIDS) are among the most common causes of drug hypersensitivity (HS) reactions. The diagnosis is based on a careful clinical history, and provocation tests are considered the gold standard for diagnosis. Skin tests have some value to study reactions to pyrazolones. Laboratory investigations are mostly used for research purposes. Different phenotypes have been described., Objective and Methods: Our aim was to describe the most common clinical manifestations of NSAID HS in a large population of adult patients, the drugs involved, the association with previously described risk factors, and the outcome of diagnostic procedures. The classification of reactions proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Drug Allergy Interest Group was adopted., Results: Acetylsalicylic acid was the drug most often involved in reactions (34%), isolated cutaneous symptoms were the most reported (60%), and immediate reactions (58%) were the most common. There was an overall female predominance (64%) and 35% of the patients were atopic. HS to NSAIDs was confirmed in 21% of the patients. The most common phenotypes encountered among HS patients were NSAID-induced urticaria/angioedema and single-NSAID-induced urticaria/angioedema or anaphylaxis. Logistic regression analysis showed that gender and atopy were not significant risk factors for HS confirmation, but diagnosis depended on the number of previous reactions, the type of reaction, and the time interval between drug intake and reaction., Conclusion: Only 21% of suspected HS reactions were confirmed after diagnostic workup. Patients describing >1 previous reaction and suffering immediate reactions had a higher probability of a positive investigation., (© 2017 S. Karger AG, Basel.)

Published
2016
Full Text
View/download PDF

24. Delayed hypersensitivity to ribavirin confirmed by provocation test.

Author

Barreira P, Cadinha S, Malheiro D, and da Silva JP

Subjects
Female, Hepatitis C, Chronic drug therapy, Humans, Middle Aged, Antiviral Agents adverse effects, Drug Hypersensitivity diagnosis, Hypersensitivity, Delayed diagnosis, Ribavirin adverse effects
Published
2014

25. Drug-induced anaphylaxis survey in Portuguese Allergy Departments.

Author

Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, Gomes E, Malheiro D, Cadinha S, Campina-Costa S, Neto M, Sousa N, Rodrigues-Alves R, Romeira A, Caiado J, and Morais-Almeida M

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Anaphylaxis epidemiology, Child, Child, Preschool, Drug Hypersensitivity epidemiology, Female, Humans, Male, Middle Aged, Portugal epidemiology, Young Adult, Anaphylaxis chemically induced, Anaphylaxis immunology, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Anti-Inflammatory Agents, Non-Steroidal immunology, Drug Hypersensitivity immunology, Hypersensitivity immunology
Abstract

Background and Objective: Drug-induced anaphylaxis is an unpredictable and potentially fatal adverse drug reaction. The aim of this study was to identify the causes of drug-induced anaphylaxis in Portugal., Methods: During a 4-year period a nationwide notification system for anaphylaxis was implemented, with voluntary reporting by allergists. Data on 313 patients with drug anaphylaxis were received and reviewed. Statistical analysis included distribution tests and multiple logistic regression analysis to investigate significance, regression coefficients, and marginal effects., Results: The mean (SD) age of the patients was 43.8 (17.4) years, and 8.3% were younger than 18 years. The female to male ratio was 2:1.The main culprits were nonsteroidal anti-inflammatory drugs (NSAIDs) (47.9% of cases), antibiotics (35.5%), and anesthetic agents (6.1%). There was a predominance of mucocutaneous symptoms (92.2%), followed by respiratory symptoms (80.4%) and cardiovascular symptoms (49.0%). Patients with NSAID-induced anaphylaxis showed a tendency towards respiratory and mucocutaneous manifestations. We found no significant associations between age, sex, or atopy and type of drug. Anaphylaxis recurrence was observed in 25.6% of cases, and the risk was higher when NSAIDs were involved., Conclusions: NSAIDs were the most common cause of anaphylaxis in this study and were also associated with a higher rate of recurrence. We stress the need for better therapeutic management and prevention of recurring episodes of drug-induced anaphylaxis.

Published
2014

26. Desensitization to clopidogrel: a tailor-made protocol.

Author

Barreira P, Cadinha S, Malheiro D, and Moreira da Silva JP

Subjects
Aged, Clopidogrel, Humans, Male, Ticlopidine adverse effects, Desensitization, Immunologic, Drug Hypersensitivity therapy, Platelet Aggregation Inhibitors adverse effects, Ticlopidine analogs & derivatives
Abstract

Clopidogrel is an antiplatelet drug widely used for treatment and prevention of a variety of cardiovascular diseases. We report a successful desensitization to clopidogrel in a 70-year-old Caucasian man with delayed hypersensitivity (HS) reaction. He developed lip, hand and foot swelling, erythematous papular non-pruritic lesions and arthralgias 2 weeks after starting treatment with clopidogrel 75 mg/d. A 3-hour desensitization protocol was started, achieving a cumulative dose of 154 mg without any reaction, and a daily dose of 75 mg was recommended. On the 4th day, the patient developed skin lesions similar to the previously described. He was treated with topical steroids and oral antihistamines, and the daily dose of clopidogrel was reduced to 20 mg. A new desensitization protocol was established, with a slow dose increment, according to the patient's response. It was only possible to achieve the dose of 75 mg/d after 2 months. Although well tolerated by most patients, HS reactions with clopidogrel may occur and desensitization is rising as a safe alternative in those patients. In delayed reactions with cutaneous lesions, a slower desensitization protocol may be necessary, as in this case.

Published
2014

27. Nonpigmented fixed drug eruption induced by esomeprazole.

Author

Morais P, Baudrier T, Mota A, Cunha AP, Cadinha S, Barros AM, and Azevedo F

Subjects
Esomeprazole, Esophagitis, Peptic drug therapy, Female, Humans, Middle Aged, Omeprazole therapeutic use, Proton Pump Inhibitors therapeutic use, Skin Pigmentation, Treatment Outcome, Drug Eruptions pathology, Omeprazole adverse effects, Proton Pump Inhibitors adverse effects
Abstract

A 56-year-old white woman developed a distinctive skin eruption over her mammary, lumbosacral, and pubic areas 2 weeks after the start of esomeprazole therapy for dyspeptic symptoms. Skin biopsy disclosed a spongiotic dermatitis with predominantly lymphocytic dermal infiltrate. Treatment with a tapering dose of corticosteroid and withdrawal of the suspected drug led to a rapid resolution of the eruption without residual dyschromia. Patch testing with esomeprazole 2% in petrolatum was negative at 48 and 72 hours but became positive on day 6. Oral-controlled provocation test induced the reappearance of the lesions over the mammary areas, confirming the putative involvement of this drug. Therefore, the patient was diagnosed as having a nonpigmented fixed drug eruption associated with esomeprazole. This compound is a proton-pump inhibitor developed as the S-isomer of omeprazole to improve its pharmacokinetic properties. Reports of cutaneous reactions to proton-pump inhibitors are quite common, but reports of such reactions to esomeprazole are rare, which demonstrates the need for higher clinical awareness and knowledge of reactions to these drugs.

Published
2010
Full Text
View/download PDF

28. Immediate hypersensitivity to penicillins with negative skin tests--the value of specific IgE.

Author

Silva R, Cruz L, Botelho C, Castro E, Cadinha S, Castel-Branco MG, and Rodrigues J

Subjects
Adult, Female, Humans, Male, Middle Aged, Penicillins adverse effects, Skin Tests, Anti-Bacterial Agents adverse effects, Drug Hypersensitivity diagnosis, Hypersensitivity, Immediate diagnosis, Immunoglobulin E blood
Abstract

The determination of specific IgE in patients with history of penicillins hypersensitivity is simple, safe and widely available. The positive and negative predictive values of this determination, however, are not yet established. In order to evaluate them, we performed specific IgE determination and diagnostic drug challenges in a group of 22 patients with a clear history of immediate penicillins hypersensitivity but negative skin tests. In this sample, the positive and negative predictive values were 29% and 87%, respectively. This seems to indicate that a positive specific IgE is not enough to confirm the diagnosis, and further study is necessary.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results